Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 14, 2009

Hospira Pays ChemGenex Roughly $16.25M Up Front for CML Therapy

  • Hospira is shelling out €11.1 million (about $16.25 million) up front as part of a licensing and co-development deal for ChemGenex’ leukemia therapy. The agreement covers omacetaxine mepesuccinate in Europe, the Middle East, and specific African countries.

    The deal could be worth another €74.1 million, or $108.46 million, to ChemGenex in performance milestones. The company will also be paid royalties on future sales of the drug.

    Marketing approval applications for omacetaxine have already been accepted for regulatory review in the U.S. and Europe. The applications cover use of the drug as a treatment for chronic myeloid leukemia in patients who demonstrate the Bcr-Abl T3151 mutation and have failed to respond to Gleevec.

    Under the terms of the agreement, ChemGenex will complete registration of omacetaxine with the EMEA. Hospira will be responsible for commercializing omacetaxine in its licensed territories. The companies will also collaborate to investigate additional applications of the drug in a range of hematological malignancies.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »